

## Special Issue

# Whole Breast Radiotherapy versus Endocrine Therapy in Early Breast Cancer

### Message from the Guest Editors

Multiple randomized trials have established adjuvant endocrine therapy and whole breast irradiation as the standard approach after breast conserving surgery in early stage breast cancer. The omission of whole breast radiotherapy has likewise been studied in multiple trials, resulting in reduced local control with maintained survival rates, and has, therefore, been adapted as a treatment option in selected patients in several guidelines. Omitting endocrine therapy instead of whole breast irradiation might also be a valuable option as both treatments have distinctly different side effect profiles. However, the clinical outcomes of breast conserving surgery and endocrine therapy versus breast conserving surgery and whole breast irradiation have not been thoroughly analyzed. In this Special Issue, we want to discuss this question.

---

### Guest Editors

Prof. Dr. Edwin Bölke

Dr. Christiane Matuschek

Dr. Stefanie Corradini

Dr. David Krug

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/83791](https://mdpi.com/si/83791)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)